Insignificant effects of loss of heterozygosity in HLA in the efficacy of immune checkpoint blockade treatment.

Background: It is assumed that loss of heterozygosity and allelic copy loss in HLA gene is associated with poor response rates in immune checkpoint inhibitor treatment. H-owever, the accurate extents or consistency in cancer types have not been explored.

Objective: The goal of this study is to investigate quantitative relationship between HLA allelic copy loss and response rates to immune checkpoint inhibitors.